Abstract: Despite widespread use and validation of their efficacy, about 40-60% of obsessive compulsive disorder (OCD) sufferers do not respond to appropriate courses of treatment with serotonin reuptake inhibitors (SRI) and even with the combination of pharmacotherapy and cognitive behaviour therapy a substantial number of patients remain dramatically symptomatic. Recently, there has been increasing interest in investigating glutamatergic dysfunction in OCD. Multiple lines of evidence point toward glutamatergic dysfunction being related to the pathophysiology of OCD, with glutamate modulating drugs being an alternative pharmacological strategy for treating OCD. In this article we focus in detail on the rationale for targeting glutamatergic agents as well as review the recent important patents for compounds that have emerged from these studies.
INTRODUCTION
Obsessive-compulsive disorder (OCD) is a severe and often chronic illness, characterised by recurrent, persistent and intrusive thoughts that cause considerable distress or anxiety (obsessions) and repetitive ritualistic behaviours or mental acts that are performed excessively (compulsions). It has a lifetime prevalence of 1.9-2.5 % across multinational sites [1] which is about twice the lifetime prevalence rates of schizophrenia [2] . Because of its high prevalence rates and the disabling nature of its symptoms, OCD has been named by the World Health Organization among the top 10 causes of years lived with illness-related disability [3] . While the economic and social burden of OCD is difficult to quantify, one study estimated it to be around $8.4 billion in the United States alone in 1990 [4] .
Although a few decades ago, OCD was considered to be almost entirely treatment-resistant, serotonin reuptake inhibitors (SRI) are now the first line pharmacological treatment at most centres [5] . In fact, efficacy of SRIs in OCD originally led to the serotonergic dysfunction hypothesis of OCD, which has now been present for over two decades [6] . However, despite widespread use and validation of their efficacy [7, 8] , about 40-60% of OCD sufferers do not respond to appropriate courses of SRI treatment [9, 10] and even with the combination of pharmacotherapy and Cognitive Behaviour therapy a substantial number of patients remain dramatically symptomatic [11] . Non-response to SRIs in a substantial number of OCD patients has led to studies investigating the role of other neurotransmitter systems as well as pharmacological agents acting on these neurotransmitter systems in OCD.
In this review, we discuss in detail on the rationale for targeting glutamatergic agents as well as the recent patents for glutamatergic compounds that have emerged from these studies.
NEUROTRANSMITTER DYSFUNCTIONS IN OCD
Various neurotransmitters and neurochemicals have been implicated in the pathophysiology of OCD. There is a growing body of literature from imaging [12] [13] [14] [15] [16] , cerebrospinal fluid (CSF) [6, 17, 18] and pharmacological challenge stu-dies [19] supporting the serotonergic dysfunction hypothesis in OCD. Clinical studies [20, 21] as well as animal models of OCD [22, 23] and findings from imaging studies [13, 15, 24, 25] have also suggested the presence of dopaminergic dysfunction in OCD. Researchers have examined the role of the opioid system [26] and neuropeptides like oxytocin and vasopressin [27, 28] in OCD although the evidence has been equivocal. Emerging evidence reviewed below has recently implicated glutamatergic dysfunction in OCD. Although, it is likely that the underlying pathophysiology of OCD is a result of complex interaction between the various neurotransmitter dysfunctions implicated in OCD, recent evidence suggesting glutamate abnormalities in OCD have however opened up new avenues for developing pharmacological approaches to treating OCD.
GLUTAMATERGIC DYSFUNCTION IN OCD
Several different lines of evidence including functional, structural, and spectroscopic brain imaging studies have implicated dysfunction in either the 'direct' or 'indirect' loops of the cortico-striato-pallido-thalamo-cortical circuit in OCD [29] . This circuit involves a complex neurotransmitter network, where dopamine, serotonin, glutamate, and GABA dysfunction have been implicated in OCD [30] . Recently, there has been increasing interest in investigating the role of glutamate in OCD, which is the primary excitatory neurotransmitter [31] , in the cortico-striatal-pallido-thalamocortical circuits and is also known to interact extensively with serotonin and dopamine [32] . Several lines of evidence summarised below have accumulated implicating dysfunction in glutamatergic systems in OCD.
EVIDENCE FROM NEUROIMAGING STUDIES
Neuroimaging evidence implicating glutamatergic dysfunction in OCD has come primarily from studies using magnetic resonance spectroscopy (MRS), a method which allows quantification of various small molecules in the brain. In one of the first reports implicating glutamatergic dysfunction in OCD, Moore et al. (1998) [33] reported striking changes in caudate Glx (a marker for combined glutamate and glutamine) resonance on proton magnetic resonance spectroscopy (1H-MRS) in a paediatric OCD patient following treatment with Paroxetine. Subsequently, Rosenberg et al. (2000) [34] studied 11 psychotropic drug-naïve children with OCD, with single-voxel 1H-MRS examinations and demonstrated that caudate Glx concentrations were significantly greater in the patients compared to healthy controls. They also found that the caudate Glx levels in patients decreased significantly following 12-weeks treatment with Paroxetine to levels comparable to that of controls and the decrease was associated with decrease in symptom severity of the OCD patients, while there was no difference in Glx levels in the occipital cortex between the two groups. In a subsequent report, Bolton et al. (2001) [35] reported that the decrease in left caudate Glx levels on 1H-MRS following 12 weeks treatment with Paroxetine persisted 3 months after medication discontinuation in an 8-year old girl, who was part of the earlier sample of Paroxetine-treated OCD patients. In a later study from the same group, there was however decrease in the absolute Glx level in the anterior cingulate of children with OCD [36] . More recently, Whiteside et al. (2006) [37] have demonstrated that within the right orbitofrontal white matter, relative levels of Glx and N-acetylaspartate were increased in adult patients with OCD compared with healthy controls and greater levels of Glx/Creatine were associated with more severe OCD symp-toms. Despite the well-known methodological shortcomings of MRS in quantification of glutamate levels [38, 39] , the results from the above studies consistently implicate glutamatergic dysfunction in OCD. Although it is unknown whether Glx concentrations are a marker of brain activity, Glx has been found to have a direct relation to brain metabolism as measured by Positron emission tomography [40] . Interestingly, if Glx is considered to represent brain activity, evidence of Glx changes as observed using MRS are also consistent with evidence from other imaging studies suggesting hyperactivity in the corticostriato-thalamo-cortical circuit or increased cortical excitability in OCD [41, 42] . Thus emerging evidence from neuroimaging studies are generally consistent in implicating glutamatergic dysfunction in OCD.
EVIDENCE FROM GENETIC STUDIES
Although, a number of family studies have established significant familial aggregation in OCD, there has not been much success in identifying candidate genes in OCD [43] [44] [45] . Until recently, results from the few genetic studies that have investigated glutamate-related candidate genes in OCD, have been mixed. Hanna et al. (2002) [46] published a genome scan based on OCD probands where they found a region suggestive of linkage (LOD score-2.25) in chromosome 9p which contains the neuronal glutamate transporter gene SLC1A1, though there was no evidence for biased transmission in OCD families. Subsequently, Arnold and colleagues (2004) [47] demonstrated a significant association between a polymorphism in the 3´ untranslated region of GRIN2B (glutamate receptor, ionotropic, N-methyl-Daspartate 2B) and OCD after correction for multiple testing, though another group did not find any association between OCD and two of the kainate subtype of glutamate receptors, GRIK2 (glutamate receptor ionotropic kainate 2) and GRIK3 (glutamate receptor ionotropic kainate 3) [48] . To put this in perspective, it is worth noting that although genes related to the serotonergic and dopaminergic system have been intensively investigated in OCD, no genetic association has been identified [49] .
However, recently two independent groups of investigators have reported statistically significant association between OCD and a locus on chromosome 9p24 that codes for a high-affinity neuronal/epithelial excitatory amino acid transporter (EAAC-1), also known as SLC1A1 (Solute carrier family 1, member 1) [50, 51] . It is thought that in the brain this transporter is crucial in terminating the action of the excitatory neurotransmitter glutamate and in maintaining extracellular glutamate concentrations within a normal range [52] . Although not conclusive, evidence from genetic studies add to the growing body of evidence implicating glutamatergic abnormalities in OCD.
EVIDENCE FROM ANIMAL MODELS
Further evidence implicating glutamatergic transmission in OCD has come from studies with animal models of OCD. McGrath et al. (2000) [53] demonstrated using the D1CT transgenic mice model of comorbid Tourette's syndrome and OCD (TS+OCD) [23] , that glutamatergic drugs such as MK-801, a non-competitive NMDA receptor antagonist, indirectly stimulate the cortical-limbic glutamate output and aggravate a transgene-dependent abnormal behaviour (repetitive climbing and leaping) in the D1CT transgenic mice [a transgenic mouse model expressing the neuropotentiating cholera toxin (CT) transgene in a subset of dopamine D1 receptor expressing neurons]. In order to determine the glutamate receptor type involved in the process the authors used NBQX, a seizure-inhibiting AMPA receptor antagonist, which only reduced the MK-801 dependent stereotypic and limbic seizure behaviour of the D1CT mice, but not their transgene-dependent behaviours. The authors concluded that their data strongly suggested that TS+OCD like behaviours are mediated by cortical-limbic glutamate dysfunction, where AMPA glutamate receptors may not play an essential part in the behavioural circuitry. They went on to predict that drugs acting on metabotropic glutamate subtype 2-3 receptors that attenuate glutamatergic output from the cortical-limbic regions may be beneficial in treating OCD. Further evidence supporting a glutamatergic dysfunction in OCD came from another study in which transgenic mice with increased glutamate output to the striatum exhibited a phenotype similar to comorbid OCD and Tourette syndrome including generalized behavioural perseveration, compulsive leaping, grooming-associated pulling and biting of skin and hair (similar to trichotillomania), and tics [54] .
EVIDENCE FROM PHARMACOLOGICAL STUDIES
Evidence has also been accumulating in recent years of the effectiveness of glutamate-modulating agents in the treatment of OCD. Poyurovsky et al. (2005) [55] used Memantine, an N-methyl-D-aspartic acid (NMDA) glutamatergic receptor antagonist, in treating a case of treatmentresistant OCD and demonstrated its therapeutic effect. The study suggested that Memantine was well tolerated and resulted in clinically significant reduction of the OCD symptom severity. Lafleur et al. (2006) [56] also published a case report of the beneficial effect of N-acetylcysteine, an amino acid derivative, in a female OCD patient, who had not responded to two previous trials of SRIs (Fluoxetine and Clomipramine) and only partially responded to a trial with a third SRI (Fluvoxamine). There was more than 20 point reduction in OCD symptom severity ratings following Nacetylcysteine augmentation of Fluvoxamine over a 12-week period of combined treatment, which persisted during follow-up 2 months later. The authors hypothesized that the benefits associated with N-acetylcysteine in this patient was related to its ability to reduce synaptic glutamatergic activity perhaps via activation of group II metabotropic glutamate receptors. There have been other studies investigating the beneficial effect of Morphine (in a double-blind trial) [57] and Tramadol hydrochloride, an opiate agonist (in a openlabel study) [58] in treatment-resistant OCD. Koran et al. (2005) [57] concluded that while mu-opioid receptor mediated disinhibition of midbrain serotonergic neurons could explain the beneficial effect of mu-receptor agonists like morphine in OCD, an alternative explanation was mureceptor mediated blockade of serotonin-induced release of excitatory neurotransmitter glutamate in the medial prefrontal cortex and other areas of brain.
The most promising glutamate-modulating agent investigated thus far in treating OCD has been Riluzole (2-amino-6-trifluro methoxy-benzthiazole) [ Fig. (1) ], a Na + channel blocker exhibiting potent anti-glutamatergic properties. Riluzole is a neuroprotective agent that inhibits the release of glutamate from nerve terminals, inactivates voltage- Fig. (1) . Riluzole. dependent sodium channels in cortical neurons and blocks GABA uptake [59, 60] . It modulates both kainate and NMDA receptors and inhibits excitotoxic injury in experimental models of cerebral ischemia, Parkinson's disease and Amyotrophic lateral sclerosis (ALS) and has been demonstrated to be neuroprotective in glutamateinduced excitotoxic cell death in vitro as well as in vivo [61, 62] . In an open label study, Riluzole was associated with significant antidepressant effects in patients with bipolar depression [63] . In a similar study, authors found Riluzole to be an effective medication for patients with generalized anxiety disorder [64] . A recent open label study demonstrated anti-obsessional effects of Riluzole in treatmentresistant OCD, which the authors concluded was related to attenuation of glutamatergic activity [65] . The authors suggested that further studies would be required to determine whether Riluzole preferentially targets components of the cortico-striato-thalamic circuitry or has a more global effect. Interestingly, a recent study showed the ability of Riluzole in reversing behavioural deficits induced by excitotoxic prefrontal cortex lesion, where the authors hypothesized that the mechanism through which Riluzole bestowed neuroprotection may involve various pathways including an inactivation of voltage-dependent sodium channels, inhibition of excitatory amino acid release through a G-protein signalling pathway and possibly, a blockade of NMDA receptors [66] .
EVIDENCE FROM CSF STUDIES
More recently, in the only published study investigating CSF glutamate levels in OCD Chakrabarty et al. (2005) [67] found CSF glutamate levels in psychotropic drug-naïve OCD patients to be significantly higher compared to psychiatrically normal controls, further implicating glutamatergic excess in the pathophysiology of OCD. While the authors did not find any relationship between OCD symptom severity and CSF glutamate levels, they opined that this was possibly because there is a complex interplay between various neurotransmitter dysfunctions rather than centrality of one neurotransmitter dysfunction in OCD, ruling out any simple correlation between OCD symptom severity scores and CSF glutamate levels. The authors also noted that though increased CSF glutamate is not the same as increased glutamatergic activity in the cortical and subcortical pathways, it is worth noting that various studies have demonstrated the existence of a blood-CSF barrier to amino acids and suggested that CSF glutamate concentrations should reflect its function within central nervous system. Available evidence reviewed thus far strongly implicates a role for glutamatergic dysfunction in OCD. Although not entirely clear, it is likely that this dysfunction is characterised by glutamatergic hyperactivity which leads to hyperactivity of the OCD circuit in the cortico-striato-pallidothalamo-cortical pathways. Attempts at reducing this hyperactivity by targeting glutamatergic receptors with pharmacological agents thus may prove beneficial as an alternative therapeutic strategy in OCD. However, because of the widespread distribution of glutamatergic receptors and glutamatergic neurotransmission, any such attempts need to carefully target receptors that specifically have an impact on pathways relevant to OCD. We shall now review briefly the pharmacology of glutamate and its receptors and evidence suggesting any potential targets for treatment in OCD.
GLUTAMATE AND ITS RECEPTORS-MOLECULAR TARGETS FOR ANTIOBSESSIONAL AGENTS
Glutamate is the major excitatory neurotransmitter in the brain and glutamatergic neurotransmission is mediated through and regulated by various receptors and transporters. They include the two different groups of receptors [68] [70] , their propensity to produce problematic side-effects, owing to ubiquitous expression of their target receptors, have prevented their clinical application in the treatment of anxiety disorders [71] [72] [73] . This has led to the idea that pharmacological agents that more selectively target glutamatergic system and suppress glutamate hyperexcitability might be better tolerated and more efficacious in treatment of anxiety [73] . Consequently the focus has shifted to metabotropic glutamate receptors as targets for development of anxiolytic drugs. Though receptors belonging to each of the groups of metabotropic glutamate receptors may be located both pre-and postsynaptically, Group I mGluRs (mGluR1 & mGluR5) are typically located post-synaptically from where they regulate neuronal excitability, while Group II mGluRs (mGluR 2 & mGluR 3) and most of Group III mGluRs (mGluR4, mGluR7, mGluR8) except mGluR6 are typically located presynaptically and are involved in the regulation of release of Glutamate or other neurotransmitters [74] . Although all three groups of mGluRs have been shown to be able to modulate glutamatergic transmission, for the purposes of this review, we shall focus on pharmacological agents acting on Group I and II mGluRs, as there are few pharmacological agents with the properties and receptor type selectivity ideal for testing the significance of the subtypes of Group III mGluRs in anxiety [73] . Interestingly, the different subtypes of Group I and II mGluRs have also been localized to areas hypothesized to be hyperactive in OCD [29] . Both mGluR1 and mGluR5 have been shown to be expressed in neocortical and limbic cortical regions, basal ganglia and thalamus [74] . Similarly, Group II mGluRs have also been shown to be expressed extensively in the striatum, neocortex and various limbic cortical regions, with moderate expression in the thalamus [74] . Activation of Group I mGluRs leads to increase in cell excitability through potentiation of NMDA responses [75] . Thus, one would expect mGluR1 and mGluR5 antagonists to normalize the increase in glutamatergic activity in areas of the brain implicated in OCD. On the other hand, activation of Group II mGluRs, which are typically located presynaptically, causes reduction in glutamatergic activity [75] . Although one would expect then that mGluR2 and mGluR3 agonists would be potential therapeutic targets in OCD, as in many other anxiety disorders [73] , it is interesting to note that available evidence as discussed below [76] , suggests beneficial effect of antagonists at Group II mGluRs in animal models of OCD.
One of the earliest evidence suggesting potential beneficial effect of pharmacological agents acting at metabotropic glutamate receptors in OCD came from Spooren et al. (2000) [77] , who examined the effect of the prototype metabotropic glutamate receptor 5 antagonist MPEP (2-methyl-6-phenylethynylpyridine) [Fig. (2) ] in animal models of anxiety. MPEP was noted to have a significant effect in the marble burying test, a well-known animal model of OCD [78] , in addition to its effect on various other animal models of anxiety. Fig. (4) ], which are group II metabotropic glutamate (mGlu) receptor antagonists, inhibited marble-burying behaviour and that this effect was significantly attenuated by a group II mGlu receptor agonist. Fig. (3) . MGS0039. Fig. (4) . LY341495.
Although, numerous pharmacological agents acting at the different groups of metabotropic glutamate receptors have been investigated for their beneficial effect on anxiety disorders in general (reviewed by Swanson et al., 2005) [73] , the available evidence from preclinical studies supporting their potential therapeutic effect specifically in OCD is limited at best. However, the limited available evidence [76, 77] coupled with current understanding about a hyperactive glutamatergic system, at least in some areas of the brain, being related to the pathophysiology of OCD, suggests a potential therapeutic role for antagonists at Group I and Group II metabotropic glutamatergic receptors in OCD. We review below some of the recent patents that have been published in this area. Most of the patents reviewed below describe compounds that are specifically active at Group I mGluRs.
PATENTS
Several patent applications and/ or registrations have been published especially over the last year presenting metabotropic glutamate receptor antagonists. Table 1) . According to the patents, these compounds are expected to be useful in the treatment of conditions associated with excitatory activation of mGluR5 receptor and for inhibiting neuronal damage caused by excitatory activation of mGluR5. AstraZeneca AB and NPS Pharmaceuticals Inc have published another patent presenting additional heteropolycyclic compounds which exhibit a high degree of potency and selectivity for individual metabotropic glutamate receptor (mGluR) subtypes [83] ( Table 1 ). The patent describes that in particular there are compounds that are potent and selective for the mGluR Group I receptor and more particularly for mGluR5. Accordingly, the compounds of the invention were expected to be useful in the prevention and/or treatment of conditions associated with excitatory activation of an mGluR Group I receptor and for inhibiting neuronal damage caused by excitatory activation of an mGluR Group I receptor, specifically when the mGluR Group I receptor is mGluR5. NPS Pharmaceuticals Inc have published another patent presenting heterpolycyclic compounds that are potent and selective antagonists for mGluR5 [84] . F. Hoffmann-La Roche. Inc. has published a patent for phenylethenyl and phenylethinyl derivatives as glutamate receptor antagonists which they applied for in Slovenia and for which they have applied for multiple patents in USA [ F. Hoffmann-La Roche has also published patents for mGluR2 antagonists as reviewed by Chaki et al. (2006) [89] .
CURRENT & FUTURE DEVELOPMENTS
Multiple lines of evidence as summarised above point towards glutamatergic dysfunction, more specifically glutamatergic hyperactivity, as being related to the pathophysiology of OCD. Thus, pharmacological approaches to modulate glutamatergic activity are likely to be beneficial in the treatment of OCD. Metabotropic glutamate receptor antagonists, especially because of their distribution in the central nervous system as well as their ability to modulate and stabilize glutamatergic hyperactivity, appear to be the most likely targets in this approach. Preclinical evidence provides support in favour of this approach to treating OCD. While metabotropic glutamatergic antagonists may have potential therapeutic applications, other pharmacologic agents acting at metabotropic glutamatergic receptors also may have important application as pharmacological probes in imaging studies of OCD and other anxiety disorders as well as depressive disorders in addition to development of pharmacological models of OCD and other anxiety disorders. Further preclinical research investigating pharmacological agents that are more specific agonists or antagonists at the various subtypes of metabotropic glutamate receptors is warranted, while clinical research needs to establish the efficacy and tolerability of the already characterised promising metabotropic glutamate receptor antagonists in OCD.
